ADPT

SEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 535,670

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 520,948

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001780851-26-000007 · form4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,522,058

F2 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance share units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001780851-26-000007 · form4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,851,658

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001229765-26-000006 · form4.xml · nonDerivative · entry 1

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,625

F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $13.84 to $13.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001820885-26-000004 · form4.xml · nonDerivative · entry 1

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 427,775

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001780854-26-000004 · form4.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 272,751

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001780664-26-000006 · form4.xml · derivative · entry 15

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 403,539

Underlying: Common Stock · 400 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000006 · form4.xml · derivative · entry 14

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,993

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 643,471

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.22 to $15.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 662,931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 662,531

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000006 · form4.xml · derivative · entry 13

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 403,939

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000006 · form4.xml · derivative · entry 12

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,715

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 647,809

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $15.15, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 678,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 666,869

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780649-26-000005 · form4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,771,280

F1 · kind: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The performance share units were granted on March 6, 2023, with respect to the three-year period ending on March 6, 2026. The issuer certified the achievement of the performance goals on March 6, 2026. The performance share units vested on March 6, 2026.

SEC source: 0001780851-26-000005 · form4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,992,324

F1 · kind: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The performance share units were granted on March 6, 2023, with respect to the three-year period ending on March 6, 2026. The issuer certified the achievement of the performance goals on March 6, 2026. The performance share units vested on March 6, 2026.

SEC source: 0001780664-26-000006 · form4.xml · derivative · entry 11

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 415,820

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000006 · form4.xml · derivative · entry 10

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136,437

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 652,147

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.83 to $15.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 683,088

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 671,207

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000002 · primary_doc.xml · derivative · entry 16

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 427,701

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000002 · primary_doc.xml · derivative · entry 15

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,159

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 10

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 575,235

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.74 to $16.30, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 606,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 594,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780660-26-000007 · form4.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 321,967

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001780664-26-000002 · primary_doc.xml · derivative · entry 14

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 439,582

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000002 · primary_doc.xml · derivative · entry 13

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 165,881

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 579,573

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.35 to $16.94, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 610,514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 598,633

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001852578-26-000002 · form4.xml · nonDerivative · entry 1

OWEN KATEY EINTERZ · CIK 0001852578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,254

SEC source: 0001780649-26-000005 · form4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,062,060

SEC source: 0001780662-26-000004 · form4.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 278,512

SEC source: 0001780660-26-000005 · form4.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,041

SEC source: 0001780664-26-000004 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 656,485

SEC source: 0001780851-26-000005 · form4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,283,104

SEC source: 0001237566-26-000001 · primary_doc.xml · nonDerivative · entry 1

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,315

SEC source: 0001274139-26-000001 · primary_doc.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,347

SEC source: 0001820885-26-000002 · form4.xml · nonDerivative · entry 2

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 469,113

SEC source: 0001820885-26-000002 · form4.xml · nonDerivative · entry 1

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 406,613

SEC source: 0001780854-26-000002 · form4.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,854

SEC source: 0001229765-26-000004 · form4.xml · nonDerivative · entry 1

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,019

SEC source: 0001780649-26-000003 · primary_doc.xml · nonDerivative · entry 4

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,934,247

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.11 to $16.23, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780649-26-000003 · primary_doc.xml · nonDerivative · entry 3

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,936,627

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $16.10, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780851-26-000003 · primary_doc.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,155,291

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.